EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparison of the DRI II and LZI I fentanyl immunoassays for in vitro clinical diagnostic use

Halimat Olaniyan, Jennifer Beckman, Elizabeth Crosby, David Shepherd, Rejwi A Dahal

Laboratory Medicine · 2026

DOI: 10.1093/labmed/lmaf079 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Laboratory Medicine, 2026. Verfasst von Halimat Olaniyan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, United States. Hauptthemen laut MEDLINE: Fentanyl, Substance Abuse Detection, Analgesics, Opioid. Die Arbeit nennt 23 Literaturangaben. Gefördert von: Department of Pathology and Laboratory Medicine Translational Research Grant (R.A.D), Indiana Clinical and Translational Sciences Institute funded, in part, National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award (J.B).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Fentanyl, a highly potent synthetic opioid, has contributed to a rapid rise in opioid-related overdoses and fatalities nationwide. Consequently, the need for accurate and timely testing for fentanyl has become critical. Immunoassay screens, reported as presumptive positive or negative, help address this need. We sought to compare the clinical performance of 2 US Food and Drug Administration (FDA)–approved fentanyl immunoassays—the Thermo Scientific DRI Fentanyl II Drugs of Abuse Assay and the Lin-Zhi International LZI Fentanyl (Q) Enzyme Immunoassay—for detection of fentanyl and its metabolites in urine, using liquid chromatography–tandem mass spectrometry (LC-MS/MS) as the reference method.

Methods

A total of 806 urine specimens were screened using 2 FDA-approved fentanyl immunoassays on Beckman Coulter DxC 700 AU Chemistry Analyzer. Of these specimens, 183 that were both positive and negative by immunoassay were further analyzed by LC-MS/MS for the presence or absence of fentanyl, norfentanyl, and 4-anilino-N-phenethylpiperidine (4-ANPP).

Results

Of the 806 specimens, 786 (98%) provided concordant results and 20 (2%) had discordant results between the 2 immunoassays. Concordance between immunoassays and LC-MS/MS was 97% for the LZI assay and 89% for the DRI assay. Among the 183 specimens tested, 4-ANPP was detected in 13 (7%).

Discussion

The 2 assays demonstrated comparable clinical utility for incorporation into a urine drug screen panel.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FentanylSubstance Abuse DetectionAnalgesics, OpioidHumansImmunoassayTandem Mass SpectrometryChromatography, Liquid

Stichwörter der Autor:innen

DRI IILZI Iconfirmation testingdrugs of abusefentanylimmunoassaymass spectrometryurine drug screen

Substanzen

FentanylAnalgesics, Opioid

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, United States.
  • Indiana University School of Medicine, Indianapolis, IN, United States.
  • Division of Clinical Chemistry, Indiana University Health Pathology Laboratory, Indianapolis, IN, United States.

Förderung

  • Department of Pathology and Laboratory Medicine Translational Research Grant (R.A.D)
  • Indiana Clinical and Translational Sciences Institute funded, in part
  • National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award (J.B)

Zitieren

APA

Olaniyan, H., Beckman, J., Crosby, E., Shepherd, D., & Dahal, R. A. (2026). Comparison of the DRI II and LZI I fentanyl immunoassays for in vitro clinical diagnostic use. Laboratory Medicine. https://doi.org/10.1093/labmed/lmaf079

Vancouver

Olaniyan H, Beckman J, Crosby E, Shepherd D, Dahal RA. Comparison of the DRI II and LZI I fentanyl immunoassays for in vitro clinical diagnostic use. Laboratory Medicine. 2026. doi:10.1093/labmed/lmaf079

BibTeX
@article{Olaniyan2026,
  author = {Olaniyan, Halimat and Beckman, Jennifer and Crosby, Elizabeth and Shepherd, David and Dahal, Rejwi A},
  title = {Comparison of the DRI II and LZI I fentanyl immunoassays for in vitro clinical diagnostic use},
  journal = {Laboratory Medicine},
  year = {2026},
  doi = {10.1093/labmed/lmaf079}
}
Kostenlos starten →